You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

The other two approved drugs in BBIO’s portfolio are Nulibry (fosdenopterin) for the treatment of molybdenum cofactor deficiency (MoCD) type and Truseltiq (infigratinib) for the treatment of ...

Brill (Proceedings of the National Academy of Sciences, 74:3248, 1977) of a low- molecular-weight iron- and molybdenum-containing component from nitrogenase, the FeMo cofactor, catalyzed extensive ...